Organoids and epithelial ovarian cancer-a future tool for personalized treatment decisions?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Organoids and epithelial ovarian cancer-a future tool for personalized treatment decisions? / Sisman, Yagmur; Schnack, Tine; Hogdall, Estrid; Hogdall, Claus.
I: Molecular and Clinical Oncology, Bind 16, Nr. 2, 29, 02.2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Organoids and epithelial ovarian cancer-a future tool for personalized treatment decisions?
AU - Sisman, Yagmur
AU - Schnack, Tine
AU - Hogdall, Estrid
AU - Hogdall, Claus
PY - 2022/2
Y1 - 2022/2
N2 - Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC.
AB - Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC.
KW - ovarian cancer
KW - organoids
KW - precision medicine
KW - drug screening
KW - targeted therapy
KW - MAINTENANCE THERAPY
KW - DOUBLE-BLIND
KW - OPEN-LABEL
KW - PHASE-3 TRIAL
KW - RECURRENT
KW - BEVACIZUMAB
KW - CHEMOTHERAPY
KW - CARCINOMA
KW - MODELS
KW - MULTICENTER
U2 - 10.3892/mco.2021.2462
DO - 10.3892/mco.2021.2462
M3 - Review
C2 - 34987799
VL - 16
JO - Molecular and Clinical Oncology
JF - Molecular and Clinical Oncology
SN - 2049-9450
IS - 2
M1 - 29
ER -
ID: 314448698